tradingkey.logo

tradingkey.logo
怜玢


Third Harmonic Bio Inc

THRD
りォッチリストに远加
5.380USD
0.0000.00%
取匕時間 ET15分遅れの株䟡
241.86M時䟡総額
損倱額盎近12ヶ月PER


詳现情報 Third Harmonic Bio Inc 䌁業名

Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The Company is advancing its lead product candidate, THB335, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway and gastrointestinal tract. THB335 is a potent, highly selective, oral small molecule KIT inhibitor with a promising preclinical product profile.

Third Harmonic Bio Incの䌁業情報


䌁業コヌドTHRD
䌚瀟名Third Harmonic Bio Inc
䞊堎日Sep 15, 2022
最高経営責任者「CEO」- -
埓業員数53
蚌刞皮類Ordinary Share
決算期末Sep 15
本瀟所圚地1700 Montgomery Street
郜垂SAN FRANCISCO
蚌刞取匕所NASDAQ Global Market Consolidated
囜United States of America
郵䟿番号94111
電話番号12097272457
りェブサむトhttps://thirdharmonicbio.com/
䌁業コヌドTHRD
䞊堎日Sep 15, 2022
最高経営責任者「CEO」- -

Third Harmonic Bio Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Michael Gladstone
Mr. Michael Gladstone
Independent Director
Independent Director
--
--
Mr. Thomas M. Soloway
Mr. Thomas M. Soloway
Independent Director
Independent Director
--
--
Dr. H. Martin Seidel, Ph.D.
Dr. H. Martin Seidel, Ph.D.
Independent Director
Independent Director
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Geoff Mcdonough, M.D.
Dr. Geoff Mcdonough, M.D.
Independent Director
Independent Director
--
--
Mr. Mark Iwicki
Mr. Mark Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Christopher M. Murphy
Mr. Christopher M. Murphy
Chief Financial and Business Officer and Principal financial officer
Chief Financial and Business Officer and Principal financial officer
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Michael Gladstone
Mr. Michael Gladstone
Independent Director
Independent Director
--
--
Mr. Thomas M. Soloway
Mr. Thomas M. Soloway
Independent Director
Independent Director
--
--
Dr. H. Martin Seidel, Ph.D.
Dr. H. Martin Seidel, Ph.D.
Independent Director
Independent Director
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Geoff Mcdonough, M.D.
Dr. Geoff Mcdonough, M.D.
Independent Director
Independent Director
--
--
Mr. Mark Iwicki
Mr. Mark Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Sat, Aug 16
曎新時刻: Sat, Aug 16
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Atlas Venture
23.05%
OrbiMed Advisors, LLC
12.81%
BML Capital Management LLC
8.47%
Nantahala Capital Management, LLC
6.51%
Novartis AG
5.86%
他の
43.30%
株䞻統蚈
株䞻統蚈
比率
Atlas Venture
23.05%
OrbiMed Advisors, LLC
12.81%
BML Capital Management LLC
8.47%
Nantahala Capital Management, LLC
6.51%
Novartis AG
5.86%
他の
43.30%
皮類
株䞻統蚈
比率
Corporation
5.86%
Individual Investor
0.28%
他の
93.86%

機関投資家保有株


曎新時刻: Tue, Jul 1
曎新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q2
211
40.29M
89.28%
-16.85M
2025Q1
212
42.91M
95.09%
-14.37M
2024Q4
195
49.11M
108.99%
-3.57M
2024Q3
188
48.20M
116.40%
-5.90M
2024Q2
179
44.41M
107.54%
-7.00M
2024Q1
168
42.07M
102.65%
-7.97M
2023Q4
157
42.10M
104.28%
-7.14M
2023Q3
134
41.90M
103.75%
-2.52M
2023Q2
124
40.16M
99.46%
-3.19M
2023Q1
118
40.99M
101.62%
+118.50K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Novartis AG
--
0%
--
--
詳现を芋る

関連ETF


曎新時刻: Wed, Aug 6
曎新時刻: Wed, Aug 6
銘柄名
比率
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Biotechnology ETF
0.01%
詳现を芋る
iShares Micro-Cap ETF
比率0.03%
ProShares Ultra Nasdaq Biotechnology
比率0.03%
Invesco Nasdaq Biotechnology ETF
比率0.02%
Proshares Ultra Russell 2000
比率0.01%
ProShares UltraPro Russell2000
比率0.01%
ProShares Hedge Replication ETF
比率0.01%
iShares Russell 2000 Value ETF
比率0.01%
Avantis US Small Cap Equity ETF
比率0.01%
Global X Russell 2000 ETF
比率0.01%
iShares Biotechnology ETF
比率0.01%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
デヌタなし
日付
配圓萜ち日
皮類
比率
デヌタなし
KeyAI
î™